Phio submits FDA briefing package for PH-762; plans Phase 2b in cutaneous squamous cell carcinoma

Phio Pharmaceuticals Corp.

Submitted meeting request and comprehensive briefing package to FDA for PH-762, supporting next stage of clinical development.
Phase 1b study formally completed; planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma.
Clinical supplies for next study expected available in Q1 2027; toxicology study dosing completed.
Nonclinical development program and integrated clinical pharmacology data included in briefing package.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.